MAQVUE TABLET 10'S

MAQVUE Tablet 10'S is commonly used to treat certain specific health conditions. Consult your doctor to know if it is right for you.

For information on the active ingredients in MAQVUE Tablet 10'S, please consult the product packaging or your pharmacist.

Potential side effects of MAQVUE Tablet 10'S may include nausea, upset stomach, or headache. If you experience any severe side effects, contact your doctor immediately.

Store MAQVUE Tablet 10'S at room temperature, away from direct sunlight and moisture. Keep out of reach of children and pets.

MAQVUE Tablet 10'S can be taken with or without food, but it is best to follow your doctor's instructions.

If you miss a dose of MAQVUE Tablet 10'S, take it as soon as you remember. If it's almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.

MAQVUE Tablet 10'S can interact with other medications. Therefore, inform your doctor about all the medications you are taking.

Consult your doctor before taking MAQVUE Tablet 10'S during pregnancy.

Consult your doctor before taking MAQVUE Tablet 10'S during breastfeeding.

The recommended dosage of MAQVUE Tablet 10'S will be determined by your doctor.

The time it takes for MAQVUE Tablet 10'S to work can vary from person to person.

Consult your doctor before taking MAQVUE Tablet 10'S for a long time.

MAQVUE Tablet 10'S is not addictive.

If you overdose on MAQVUE Tablet 10'S, seek immediate medical attention.

Consult your doctor before drinking alcohol while taking MAQVUE Tablet 10'S.

Maqvue Tablet is an oral supplement containing MaquiBright, a standardized extract of Maqui berry (Aristotelia chilensis) rich in anthocyanins. It is generally used to support eye surface comfort, help relieve symptoms of dry or tired eyes, and provide antioxidant support for ocular health. It is typically used as an adjunct to standard dry eye measures, not as a replacement for prescribed ophthalmic treatments.

In most markets, Maqvue Tablet is positioned as a dietary or herbal supplement rather than a conventional prescription medicine. This means it may not undergo the same level of regulatory evaluation as a drug. Its composition and claims are based on the MaquiBright Maqui berry extract and available clinical and preclinical data, which are still limited compared with established pharmacological therapies.

Maqvue Tablet contains MaquiBright, which is rich in delphinidin‑type anthocyanins with antioxidant and anti‑inflammatory properties. These compounds are thought to help reduce oxidative stress and low‑grade inflammation on the ocular surface and lacrimal glands, potentially improving tear secretion and tear film stability. This may translate into reduced symptoms such as dryness, burning, grittiness, and visual fatigue in some users. However, the exact mechanism in humans is not fully established and evidence is based on small clinical studies.

No. Maqvue Tablet should not be used as a substitute for lubricating eye drops, prescription eye medicines, or other treatments recommended by an eye specialist. It may be used as an adjunctive supplement to support eye comfort, but established therapies for dry eye disease, allergic eye disease, glaucoma, or other ocular conditions must be continued as prescribed unless a doctor advises otherwise.

Maqvue Tablet is generally intended for adults who experience symptoms of dry, tired, or strained eyes, such as office workers with prolonged screen exposure or individuals in air‑conditioned or low‑humidity environments. It is not routinely recommended for children or adolescents unless specifically advised by a doctor. People with chronic illnesses, those taking multiple medicines, and older adults should seek medical advice before starting the supplement.

Maqvue Tablet is usually well tolerated when taken at recommended amounts. Possible side effects, based on experience with MaquiBright and similar berry extracts, may include mild gastrointestinal discomfort, nausea, stomach upset, or headache. Allergic reactions such as rash, itching, swelling, or breathing difficulty are possible but appear to be uncommon. If any severe or persistent adverse effects occur, the supplement should be stopped and medical attention sought.

Safety data for MaquiBright‑containing supplements like Maqvue Tablet in pregnancy are very limited. Because controlled studies in pregnant women are lacking, use during pregnancy cannot be considered clearly safe. Pregnant women or those planning pregnancy should consult an obstetrician or healthcare professional before using Maqvue Tablet, and in many cases it may be preferable to avoid it unless there is a clear clinical rationale and medical supervision.

There is insufficient information on the excretion of MaquiBright components into human breast milk and their effects on the breastfed infant. For this reason, routine use of Maqvue Tablet during breastfeeding is not recommended without medical advice. A healthcare professional should weigh the potential benefits for the mother against any theoretical risks to the infant before advising on its use.

Robust clinical interaction studies with Maqvue Tablet are not available. However, Maqui berry extracts have antioxidant and potential mild anti‑inflammatory effects, and there is theoretical potential for interaction with medicines that affect blood clotting, blood pressure, or glucose metabolism. People taking anticoagulants, antiplatelet agents, antihypertensives, antidiabetic medicines, or other long‑term therapies should consult a doctor or pharmacist before starting Maqvue Tablet and should not change any prescribed treatment without medical guidance.

Clinical studies with MaquiBright‑based supplements have typically evaluated outcomes over several weeks to a few months. Some individuals may notice improvement in eye comfort within a few weeks, while others may not experience a clear benefit. Because long‑term safety and efficacy data are limited, prolonged continuous use should be periodically reviewed with a healthcare professional, especially in people with underlying medical conditions or those taking multiple medicines.

Maqvue Tablet is generally taken orally and can usually be taken with water, with or without food, depending on individual tolerance and the specific product instructions. Taking it with food may reduce the likelihood of stomach upset in sensitive individuals. There are no well‑documented direct interactions with moderate alcohol intake, but combining any supplement with heavy or chronic alcohol use is not advisable, particularly in people with liver disease. Users should follow the product label and seek medical advice if unsure.